abl1-tyrosine kinase inhibitors (tkis) & chronic myeloid leukemia (cml)
Published 6 years ago • 88 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
3:15
tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
-
4:42
chronic myeloid leukemia (cml) - treatment - tyrosine kinase (tk) inhibitors
-
5:41
bcr-abl1-targeted tkis in treatment of cml
-
8:00
chronic myeloid leukemia etiology. mechanism of tyrosine kinase pathway how bcr-abl1 is formed
-
4:33
optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
-
3:12
second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
-
9:08
selecting a tyrosine kinase inhibitor in chronic myeloid leukemia case study
-
1:12
abl001 – a new bcr-abl inhibitor for chronic myeloid leukemia (cml) treatment
-
2:40
targeting tki-resistant cml with ly3009120 and asciminib
-
1:05
feasibility of treatment cessation in patients with cml with atypical bcr-abl fusion transcripts
-
2:03
update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
-
2:18
taking your tki / cml and tyrosine kinase inhibitors / chronic myeloid leukemia treatment
-
4:20
tyrosine kinase inhibitors (tkis) - imatinib (gleevec) - pharmacology - cml and all
-
1:08
ngs for kd mutational analysis in cml patients on tkis
-
5:34
second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia
-
1:38
outlook for the management of chronic myeloid leukemia
-
2:32
outcomes of patients with cml with no molecular response within two years of tki therapy
-
1:08
cml news to look out for at ash 2021
-
1:47
state of the art in cml